$UAA

Under Armour Reports Net Income In Q1; Updates FY27 Outlook

Under Armour reported Q1 net income of $1 million versus a $2.6 million loss a year earlier. Non-GAAP net income rose to $20.99 million from $8.57 million. Revenue fell 3% to $1.1 billion. The company recorded $6 million in restructuring and transformation charges and expects its plan to be largely complete by Dec. 31, 2026. It cut FY27 revenue outlook to a mid-single-digit decline and widened diluted EPS loss to -$0.01 to -$0.05.

Original reporting
Published Aug 7, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 12:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Under Armour Reports Net Income In Q1; Updates FY27 Outlook — source image
Decision brief

The 30-second read

$UAABearishMed
01

Why it matters

The key tradable update is the FY27 outlook revision, driven by softer demand in North America and Asia-Pacific, with a wider diluted loss per share range while adjusted EPS ex-charges stays unchanged.

02

Market read

Investors are likely to reprice FY27 earnings risk based on the guidance cut and demand commentary, even as adjusted EPS ex-charges remains steady.

03

What to watch

The plan is expected to be substantially complete by Dec 31, 2026, so investors may be underpricing the potential for later margin normalization beyond FY27.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Under Armour posted Q1 results with improved GAAP profitability but declining revenue, alongside restructuring and transformation-related costs.

Company-level read

Ticker impact

$UAABearishMedium confidence
Context

Under Armour reported Q1 net income improvement but cut FY27 revenue outlook to a mid-single-digit decline and widened DPS loss range.

Expected impact

Likely continued pressure on the stock until investors see demand stabilization or clearer margin offset from restructuring.

Evidence & confidence

The article’s newest decision is the FY27 outlook update, including softer demand in North America and Asia-Pacific and a wider diluted loss per share range, which typically drives estimate revisions.

Market effects

Signals ongoing apparel/athletic demand softness and restructuring-driven margin support may not fully offset top-line weakness.

Highlights weakness specifically in North America and Asia-Pacific, which can influence regional consumer discretionary sentiment.

Moderate read-through for global sportswear demand expectations and restructuring effectiveness among peers.

Counterpoint

Non-GAAP adjusted EPS guidance remains $0.08 to $0.12, suggesting restructuring and cost actions could cushion earnings despite revenue softness.

Key entities

  • Under Armour

    Reported Q1 results and updated FY27 outlook, including weaker revenue expectations and revised diluted loss per share range.

Related articles

$UAAMedAI 8/10

Under Armour forecasts steeper annual sales decline on weak North America demand

Under Armour forecast a mid-single-digit full-year revenue decline, versus a prior slight decline, citing weaker North America demand and cautious consumer spending. North America revenue fell 9% to $609.8M in the quarter ended June 30. Quarterly revenue declined 3% to $1.10B; adjusted EPS was 5 cents. The company reported $266M restructuring costs and expects the plan to finish by year-end.

$UAAMedAI 8/10

Under Armour forecasts steeper annual sales decline

Under Armour forecast a steeper annual revenue decline, citing weak consumer spending in North America amid macro uncertainty. Reuters reports North America net revenue fell 9% to $609.8 million for the quarter ended June 30. The company expects full-year revenue to decline by mid-single digits versus a prior “slight decline” target. Shares were down about 5% premarket.

$CVNAMedAI 8/10

Former penny stock nearing bankruptcy reports record profit

Carvana (CVNA) reported record Q2 2026 results, including revenue of $7.4 billion, net income of $513 million, and operating income of $680 million, with adjusted EBITDA reaching a $3 billion annual run rate. The company cited a turnaround in balance sheet and cash flow. Analysts cited mixed reactions, with Barclays and Wells Fargo cutting targets while Needham reiterated Buy.

$DKLMedAI 8/10

Delek Logistics Partners, LP Q2 2026 Earnings Call Summary

Delek Logistics Partners (DKL) reported record Q2 2026 adjusted EBITDA of $144 million, citing higher Delaware crude volumes and improved Libby gas utilization. It reaffirmed full-year 2026 adjusted EBITDA guidance of $520 million to $560 million, announced a $1.135 per-unit distribution, issued $800 million senior notes, and discussed growth from sour gas and produced-water services.

$DAVEMedAI 8/10

Dave Q2 Earnings Call Highlights

Dave Inc. (NASDAQ:DAVE) reported Q2 metrics and discussed pricing changes, ExtraCash limit increases, and rolling out CashAI v6 to about one-third of users. Non-GAAP gross profit rose 34% to $124M, and 28-day past-due improved to 2.12%. Provision for credit losses was $29M. Dave raised 2026 guidance: revenue $725M-$735M, adj. EBITDA $315M-$325M, adj. diluted EPS $17.00-$17.50.

$XBIOMed

Xenetic Biosciences, Inc.: Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Pla

Xenetic Biosciences (NASDAQ:XBIO) reported Q2 2026 results for the quarter ended June 30. Royalty revenue rose about 12% to about $0.7M, while R&D fell about 16% to about $0.6M. G&A increased about 64% to about $1.1M, driving a net loss of about $0.9M. Cash was about $6.5M. The company cited ASCO preclinical/translational data and a PeriNess study approval.